Washington, D.C. 20549







Date of Report (Date of earliest event Reported): March 4, 2019


BioCorRx Inc.

(Exact Name of Registrant as Specified in Charter)







(State or Other Jurisdiction

of Incorporation)



File Number)


(I.R.S. Employer

Identification Number)


2390 East Orangewood Avenue, Suite 575

Anaheim, California 92806

(Address of Principal Executive Offices) (Zip Code)


(714) 462-4880

(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 


Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 1.01 Entry into a Material Definitive Agreement. 


Subscription Agreement


On March 1, 2019, BioCorRx Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement dated February 22, 2019, (the “Subscription Agreement”) with an individual (the “Investor”), pursuant to which: (i) the Investor purchased shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in the aggregate amount of $100,000 at a purchase price of $4.50 per share (the “Purchase Price”), for a total of 22,222 shares of Common Stock; and (ii) the Company shall deliver 1,000 duly and validly issued, fully paid and non-assessable inducement shares to the Investor (the “Inducement Shares”), containing an appropriate restrictive legend.


The Purchase Price was paid in cash by the Investor to the Company on March 4, 2019.


The foregoing description of the Subscription Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Subscription Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.


Item 3.02 Unregistered Sales of Equity Securities. 


The applicable information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02.


The shares of Common Stock issued pursuant to the Subscription Agreement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) and are “restricted securities” as that term is defined by Rule 144 promulgated under the Securities Act.


The issuance of the Securities set forth herein was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act for the offer and sale of securities not involving a public offering. The Company’s reliance upon Section 4(a)(2) of the Securities Act in issuing the Securities was based upon the following factors: (a) the issuance of the Securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the Securities by the Company; (d) the Securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the Securities took place directly between the individual and the Company; and (f) the recipient of the Securities is an accredited investor.


Item 9.01. Financial Statements and Exhibits.


Exhibit No.





Subscription Agreement dated February 22, 2019








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



BioCorRx Inc.




Date: March 8, 2019


/s/ Lourdes Felix 



Lourdes Felix



Chief Financial Officer